In the last trading session, 1.26 million shares of the Dyne Therapeutics Inc (NASDAQ:DYN) were traded, and its beta was 1.09. Most recently the company’s share price was $14.48, and it changed around -$0.89 or -5.79% from the last close, which brings the market valuation of the company to $1.47B. DYN currently trades at a discount to its 52-week high of $47.45, offering almost -227.69% off that amount. The share price’s 52-week low was $13.23, which indicates that the current value has risen by an impressive 8.63% since then. We note from Dyne Therapeutics Inc’s average daily trading volume that its 10-day average is 2.9 million shares, with the 3-month average coming to 1.71 million.
Dyne Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.25. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended DYN as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Dyne Therapeutics Inc is expected to report earnings per share of -0.91 for the current quarter.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Instantly DYN has showed a red trend with a performance of -5.79% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 17.17 on recent trading dayincreased the stock’s daily price by 15.67%. The company’s shares are currently down -38.54% year-to-date, but still up 4.40% over the last five days. On the other hand, Dyne Therapeutics Inc (NASDAQ:DYN) is -37.18% down in the 30-day period. We can see from the shorts that 9.4 million shares have been sold at a short interest cover period of 5.56 day(s).
The consensus price target as assigned by Wall Street analysts is $52.5, which translates to bulls needing to increase their stock price by 72.42% from its current value. Analyst projections state that DYN is forecast to be at a low of $52 and a high of $53.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -106.26%. Dyne Therapeutics Inc earnings are expected to increase by 12.26% in 2025, but the outlook is positive 1.02% per year for the next five years.
DYN Dividends
Dyne Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.87% of Dyne Therapeutics Inc shares, and 112.51% of them are in the hands of institutional investors. The stock currently has a share float of 113.50%. Dyne Therapeutics Inc stock is held by 289.0 institutions, with ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC being the largest institutional investor. By 2024-06-30, it held 9.8961% of the shares, which is about 8.02 million shares worth $283.03 million.
FCPM III SERVICES B.V., with 9.6804% or 7.85 million shares worth $276.86 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 2.65 shares worth $38.44 million, making up 2.61% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.29 shares worth around $33.15 million, which represents about 2.25% of the total shares outstanding.
